176 reports of this reaction
3.5% of all POLYMYXIN B SULFATE reports
#5 most reported adverse reaction
MALAISE is the #5 most commonly reported adverse reaction for POLYMYXIN B SULFATE, manufactured by FOSUN PHARMA USA INC. There are 176 FDA adverse event reports linking POLYMYXIN B SULFATE to MALAISE. This represents approximately 3.5% of all 5,004 adverse event reports for this drug.
Patients taking POLYMYXIN B SULFATE who experience malaise should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MALAISE is moderately reported among POLYMYXIN B SULFATE users, representing a notable but not dominant share of adverse events.
In addition to malaise, the following adverse reactions have been reported for POLYMYXIN B SULFATE:
The following drugs have also been linked to malaise in FDA adverse event reports:
MALAISE has been reported as an adverse event in 176 FDA reports for POLYMYXIN B SULFATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MALAISE accounts for approximately 3.5% of all adverse event reports for POLYMYXIN B SULFATE, making it a notable side effect.
If you experience malaise while taking POLYMYXIN B SULFATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.